Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?

References

• SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin201565152925559415
   PubMed Web of Science ®Google Scholar
• SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
   PubMed Web of Science ®Google Scholar
• SiegelRLMillerKDJemalACancer statistics, 2017CA Cancer J Clin201767173028055103
   PubMed Web of Science ®Google Scholar
• KamisawaTWoodLDItoiTTakaoriKPancreatic cancerLancet201638810039738526830752
   PubMed Web of Science ®Google Scholar
• NeuzilletCTijeras-RaballandABourgetPState of the art and future directions of pancreatic ductal adenocarcinoma therapyPharmacol Ther20151558010426299994
   PubMed Web of Science ®Google Scholar
• BurrisHA3rdMooreMJAndersenJImprovements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialJ Clin Oncol1997156240324139196156
   PubMed Web of Science ®Google Scholar
• ConroyTDesseigneFYchouMGroupe Tumeurs Digestives of Unicancer; PRODIGE IntergroupFOLFIRINOX versus gemcitabine for metastatic pancreatic cancerN Engl J Med2011364191817182521561347
   PubMed Web of Science ®Google Scholar
• Von HoffDDErvinTArenaFPIncreased survival in pancreatic cancer with nabpaclitaxel plus gemcitabineN Engl J Med2013369181691170324131140
   PubMed Web of Science ®Google Scholar
• DahanLBonnetainFYchouMFédération Francophone de Cancérologie DigestiveCombination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)Gut201059111527153420947887
   PubMed Web of Science ®Google Scholar
• OettleHRiessHStielerJMSecond-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trialJ Clin Oncol201432232423242924982456
   PubMed Web of Science ®Google Scholar
• Wang-GillamALiCPBodokyGNAPOLI-1 Study GroupNanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trialLancet20163871001854555726615328
   PubMed Web of Science ®Google Scholar
• GillSKoYJCrippsCPANCREOX: a Randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapyJ Clin Oncol201634323914392027621395
   PubMed Web of Science ®Google Scholar
• CiuleanuTEPavlovskyAVBodokyGA randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabineEur J Cancer20094591589159619188061
   PubMed Web of Science ®Google Scholar
• PelzerUSchwanerIStielerJBest supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study groupEur J Cancer201147111676168121565490
   PubMed Web of Science ®Google Scholar
• AndroulakisNSyrigosKPolyzosAHellenic Oncology Research GroupOxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II studyCancer Invest200523191215779862
   PubMed Web of Science ®Google Scholar
• BoeckSWeigang-KöhlerKFuchsMSecond-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trialAnn Oncol200718474575117229775
   PubMed Web of Science ®Google Scholar
• MorizaneCOkusakaTFuruseJA phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancerCancer Chemother Pharmacol200963231331918398614
   PubMed Web of Science ®Google Scholar
• SudoKYamaguchiTNakamuraKPhase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancerCancer Chemother Pharmacol201167224925420352216
   PubMed Web of Science ®Google Scholar
• YiSYParkYSKimHSIrinotecan monotherapy as second-line treatment in advanced pancreatic cancerCancer Chemother Pharmacol20096361141114518839175
   PubMed Web of Science ®Google Scholar
• KoAHTemperoMAShanYSA multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancerBr J Cancer2013109492092523880820
   PubMed Web of Science ®Google Scholar
• BoeckSWilkowskiRBrunsCJOral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancerOncology2007733–422122718424886
   PubMed Web of Science ®Google Scholar
• HoseinPJde Lima LopesGJrPastoriniVHA phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancerAm J Clin Oncol201336215115622307213
   PubMed Web of Science ®Google Scholar
• PelzerUStielerJRollLSecond-line therapy in refractory pancreatic cancer. results of a phase II studyOnkologie20093239910219295247
   PubMedGoogle Scholar
• TsavarisNKosmasCSkopelitisHSecond-line treatment with oxali-platin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II studyInvest New Drugs200523436937516012797
   PubMed Web of Science ®Google Scholar
• NovarinoASatolliMAChiappinoIOxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancerAm J Clin Oncol2009321444819194124
   PubMed Web of Science ®Google Scholar
• El-HadaadHAWahbaHAOxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II studyJ Gastrointest Cancer201344331331723606201
   PubMedGoogle Scholar
• YooCHwangJYKimJEA randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancerBr J Cancer2009101101658166319826418
   PubMed Web of Science ®Google Scholar
• XiongHQVaradhacharyGRBlaisJCHessKRAbbruzzeseJLWolffRAPhase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancerCancer200811382046205218756532
   PubMed Web of Science ®Google Scholar
• CantoreMRabbiCFiorentiniGCombined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancerOncology2004672939715539911
   PubMed Web of Science ®Google Scholar
• ReniMPasettoLAprileGRaltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancerBr J Cancer200694678579116508631
   PubMed Web of Science ®Google Scholar
• DemolsAPeetersMPolusMGemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II studyBr J Cancer200694448148516434988
   PubMed Web of Science ®Google Scholar
• EttrichTJPerkhoferLvon WichertGDocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinomaBMC Cancer2016162126772812
   PubMed Web of Science ®Google Scholar
• KimHJYunJKimHJPhase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patientsOncol Lett2012361314131822783441
   PubMed Web of Science ®Google Scholar
• StathopoulosGPBoulikasTVougioukaMRigatosSKStathopoulosJGLiposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I–II studyOncol Rep20061551201120416596187
   PubMed Web of Science ®Google Scholar
• Ulrich-PurHRadererMVerena KornekGIrinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinomaBr J Cancer20038881180118412698181
   PubMed Web of Science ®Google Scholar
• ReniMPanucciMGPassoniPSalvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trialCancer Invest200422568869615581049
   PubMed Web of Science ®Google Scholar
• KoAHDitoESchillingerBVenookAPBergslandEKTemperoMAExcess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II studyCancer Invest2008261475218181045
   PubMed Web of Science ®Google Scholar
• ZaniboniAAitiniEBarniSFOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II studyCancer Chemother Pharmacol20126961641164522576338
   PubMed Web of Science ®Google Scholar
• SonbolMBFirwanaBWangZSecond-line treatment in patients with pancreatic ductal adenocarcinoma: a meta-analysisCancer2017123234680468628817187
   PubMed Web of Science ®Google Scholar
• RothenbergMLBenedettiJKMacdonaldJSPhase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group studyAnn Oncol200213101576158212377645
   PubMed Web of Science ®Google Scholar
• KimYJBangSParkJYParkSWChungJBSongSYPhase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancerCancer Chemother Pharmacol200963352953318766341
   PubMed Web of Science ®Google Scholar
• KatopodisOPolyzosAKentepozidisNSecond-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trialCancer Chemother Pharmacol201167236136820428874
   PubMed Web of Science ®Google Scholar
• SoaresHPBayraktarSBlayaMA phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTereCancer Chemother Pharmacol201473483984524562589
   PubMed Web of Science ®Google Scholar
• GeFXuNBaiYS-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II studyOncologist201419111133113425273077
   PubMed Web of Science ®Google Scholar
• UenoMOkusakaTOmuroYA randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancerAnn Oncol201627350250826681680
   PubMed Web of Science ®Google Scholar
• OhkawaSOkusakaTIsayamaHRandomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancerBr J Cancer201511291428143425880004
   PubMed Web of Science ®Google Scholar
• IokaTKomatsuYMizunoNRandomized phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancerBr J Cancer2017116446447128081543
   PubMed Web of Science ®Google Scholar
• CeredaSReniMRognoneASalvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trialChemotherapy201157215616121454973
   PubMed Web of Science ®Google Scholar
• BraghiroliMIde Celis FerrariACPfifferTEPhase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreasEcancermedicalscience2015956326316884
   PubMed Web of Science ®Google Scholar
• MooreMJGoldsteinDHammJNational Cancer Institute of Canada Clinical Trials GroupErlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol200725151960196617452677
   PubMed Web of Science ®Google Scholar
• RenoufDJTangPAHedleyDA phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancerEur J Cancer201450111909191524857345
   PubMed Web of Science ®Google Scholar
• KulkeMHBlaszkowskyLSRyanDPCapecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancerJ Clin Oncol200725304787479217947726
   PubMed Web of Science ®Google Scholar
• KoAHBekaii-SaabTVan ZiffleJA multicenter, open-label phase II clinical trial of combined MEK plus EGFR inhibition for chemotherapy-refractory advanced pancreatic adenocarcinomaClin Cancer Res2016221616826251290
   PubMed Web of Science ®Google Scholar
• KoAHVenookAPBergslandEKA phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancerCancer Chemother Pharmacol20106661051105720130876
   PubMed Web of Science ®Google Scholar
• JavleMMShroffRTXiongHInhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studiesBMC Cancer20101036820630061
   PubMed Web of Science ®Google Scholar
• IgnatiadisMPolyzosAStathopoulosGPA multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancerOncology2006713–415916317646699
   PubMed Web of Science ®Google Scholar
• BrellJMMatinKEvansTPhase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancerOncology200976427027419258727
   PubMed Web of Science ®Google Scholar
• WuZGabrielsonAHwangJJPhase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancerCancer Chemother Pharmacol20157661309131426507197
   PubMed Web of Science ®Google Scholar
• Van CutsemEVervenneWLBennounaJPhase III trial of beva-cizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancerJ Clin Oncol200927132231223719307500
   PubMed Web of Science ®Google Scholar
• AstsaturovIAMeropolNJAlpaughRKPhase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinomaAm J Clin Oncol2011341707520458210
   PubMed Web of Science ®Google Scholar
• O’ReillyEMNiedzwieckiDHallMCancer and Leukemia Group BA Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603)Oncologist201015121310131921148613
   PubMed Web of Science ®Google Scholar
• DragovichTLaheruDDayyaniFPhase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)Cancer Chemother Pharmacol201474237938724939212
   PubMed Web of Science ®Google Scholar
• BodokyGTimchevaCSpigelDRA phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapyInvest New Drugs20123031216122321594619
   PubMed Web of Science ®Google Scholar
• ChungVMcDonoughSPhilipPAEffect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trialJAMA Oncol20173451652227978579
   PubMed Web of Science ®Google Scholar
• HurwitzHIUppalNWagnerSARandomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failedJ Clin Oncol201533344039404726351344
   PubMed Web of Science ®Google Scholar
• HurwitzHVan CutsemEBendellJRuxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studiesInvest New Drugs Epub201836
   Web of Science ®Google Scholar
• WolpinBMHezelAFAbramsTOral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancerJ Clin Oncol200927219319819047305
   PubMed Web of Science ®Google Scholar
• ArcaroliJQuackenbushKDasariABiomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of sara-catinib, an oral Src inhibitor, in previously treated pancreatic cancerCancer Med20121220721723342270
   PubMed Web of Science ®Google Scholar
• CarvajalRDTseAShahMAA phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancerPancreatology20099440440919451750
   PubMed Web of Science ®Google Scholar
• PinoMSMilellaMGelibterACapecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancersOncology200976425426119246950
   PubMed Web of Science ®Google Scholar
• ChawlaSPChuaVSFernandezLAdvanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancerMol Ther201018243544119826403
   PubMed Web of Science ®Google Scholar
• RamanathanRKAbbruzzeseJDragovichTA randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combinationCancer Chemother Pharmacol201167350350920461382
   PubMed Web of Science ®Google Scholar
• WuJZhangMLiuDAcalabrutinib (ACP-196): a selective second-generation BTK inhibitorJ Hematol Oncol201692126957112
   PubMed Web of Science ®Google Scholar
• BachetJBGayFMaréchalRAsparagine synthetase expression and phase I study with L-asparaginase encapsulated in red blood cells in patients with pancreatic adenocarcinomaPancreas20154471141114726355551
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma, V.3.2017 Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdfAccessed December 10, 2017
   Google Scholar
• PortalAPernotSTougeronDNab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohortBr J Cancer2015113798999526372701
   PubMed Web of Science ®Google Scholar
• ZhangYHochsterHSteinSLacyJGemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicityExp Hematol Oncol201542926451276
   PubMed Web of Science ®Google Scholar
• ReniMCeredaSMilellaMMaintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trialEur J Cancer201349173609361523899530
   PubMed Web of Science ®Google Scholar
• SinnMDälkenLStrieflerJKSecond-line treatment in pancreatic cancer patients: who profits? – Results from the CONKO study groupPancreas201645460160526646276
   PubMed Web of Science ®Google Scholar
• VienotABeinseGLouvetCOverall survival prediction and usefulness of second-line chemotherapy in advanced pancreatic adeno-carcinomaJ Natl Cancer Inst201710910
   Google Scholar